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Raspberries are a rich source of ellagitannins and anthocyanins. The aim of this work was to 3 
investigate whether raspberry consumption can improve vascular function and to understand 4 
which phenolic metabolites may be responsible for the effects. A 3 arm double-blind randomized 5 
controlled crossover human intervention trial was conducted in 10 healthy males. Flow-mediated 6 
dilation (FMD) was measured at baseline, 2 h, and 24 h post-consumption of  200 g and 400 g of 7 
red raspberries containing 201 or 403 mg of total (poly)phenols, or a matched control drink. 8 
Raspberry (poly)phenol metabolites were analyzed in plasma and urine by UPLC-QTOF mass 9 
spectrometry using authentic standards. Significant improvements in FMD were observed at 2 h 10 
(1.6% (95%CI 1.2, 1.9) and 1.2% (95% CI 0.8, 1.5)) and 24 h (1.0% (95% CI 0.6, 1.2)  and 0.7% 11 
(95%CI 0.2, 0.9)) post-consumption of the 200 and 400 g raspberry drinks as compared to 12 
control, respectively. Plasma ellagic acid, urolithin A-3-glucuronide and urolithin A-sulfate 13 
correlated with the improvements in FMD at 2 and 24 h post consumption, respectively. 14 
Consumption of dietary achievable amounts of red raspberries acutely improves endothelial 15 
function up to 24 h and ellagitannins may be responsible for the observed effect.   16 
 17 
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Red raspberries are one of the most common berry fruits consumed in the US with a yearly 24 
average availability of 560 g per capita in 2015 and still increasing in popularity today 25 
(https://www.ers.usda.gov). Despite being a very popular fruit, to our knowledge no clinical 26 
study has been published investigating the vascular effects of red raspberries in human subjects, 27 
although a number of preclinical studies have indicated potential health benefits (1-4).  28 
Red raspberries are good sources of putatively bioactive (poly)phenolic compounds, including 29 
ellagitannins and anthocyanins (5, 6), which have been associated with lower cardiovascular 30 
disease (CVD) risk according to recent meta-analyses (7, 8). Evidence from randomized 31 
controlled trials with ellagitannin-rich sources (i.e. strawberries, pomegranate, and walnuts) have 32 
shown improvements in surrogate biomarkers of cardiovascular risk such as blood lipids, 33 
glycemic index, and blood pressure in at-risk individuals (9-14). The bioavailability of 34 
(poly)phenols in plasma is mainly characterized by an early absorption in the small intestine 35 
followed by a late colonic uptake. As early as 1 h after red raspberry consumption, ellagic acid 36 
was reported in plasma in low nanomolar concentrations (15). Most of the ellagitannins, 37 
however, travel further down the intestine and reach the colon after a few hours where they are 38 
transformed into urolithin catabolites by colonic microbiota (16). In contrast to other phenolic 39 
compounds, urolithins remain in the circulation for up to 80 hours after consumption (17, 18).  40 
Anthocyanins, also present in red raspberries, were shown to be absorbed and metabolized – both 41 
in the early and later phases - with main phenolic breakdown products and metabolites identified 42 
in urine and plasma as cinnamic acids, hippuric acids, phenylacetic acids, phenylpropionic acids, 43 
and benzoic acids (19, 20). 44 
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In the current study, we aimed to investigate the potential vascular benefits of red raspberries in 45 
healthy humans and identify which of the berry (poly)phenol metabolites may be responsible for 46 




SUBJECTS AND METHODS 49 
Study subjects 50 
Ten healthy male volunteers aged 18 to 35 years were recruited from the University of 51 
Düsseldorf and surrounding area. Health was ascertained by a routine clinical physical exam and 52 
specific cardiovascular history performed by a cardiovascular specialist. Manifest cardiovascular 53 
disease including coronary artery disease, cerebrovascular disease, and peripheral artery disease, 54 
diabetes mellitus, acute inflammation, terminal renal failure, malignancies, and heart rhythm 55 
other than sinus were exclusion criteria.  56 
 57 
Study Design 58 
A three-arm, double blind, crossover randomized controlled trial was conducted. Informed 59 
consent was obtained and subjects were randomized to the treatments. We investigated the 60 
vascular effects of 200 g and 400 g of frozen red raspberries compared with a matched control 61 
drink. Measurements were taken at baseline, at 2 h, and at 24 h post-acute consumption. Blood 62 
samples were drawn at all time points for measuring plasma raspberry (poly)phenol metabolites. 63 
A 24 h urine sample was collected throughout each of the study days. Volunteers were instructed 64 
not to alter their usual dietary or fluid intake. The 10 volunteers selected for the study were asked 65 
to refrain from the following: consumption of (poly)phenol-rich foods including fruits, 66 
vegetables, cocoa, chocolate, coffee, tea and wine 24 h prior to the study, participating in 67 
vigorous exercise (> 3 x 20 min per week) and consuming more than 168 g of alcohol (any form) 68 
per week. Compliance to the diet and lifestyle restrictions was determined via a 24 h-dietary 69 
recall and via interview. At the end of the clinical exams, i.e. after completion of 2 h 70 
measurements, all subjects were given low nitrate mineral water and foods low in (poly)phenols 71 
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for lunch and dinner (lunch consisted of chicken slices, cheese, one boiled egg, and a low fat 72 
yoghurt; dinner consisted of ready made macaroni and cheese). They were instructed to drink 73 
water ad libitum, to eat only the given foods and to overnight fast for at least 12 hours prior to 74 
the 24 h measurement was made on the following day.  75 
The primary endpoint was an improvement of endothelial vasodilator function as measured by 76 
flow-mediated vasodilation (FMD) using high-resolution ultrasound. Secondary endpoints were 77 
improvements in key determinants of vascular function and included decreases in pulse wave-78 
velocity (PWV), aortic augmentation index (AIX), and blood pressure (ambulatory and central) 79 
as determined automatically by a blood pressure monitoring system and applanation tonometry 80 
(Sphygmocor). Tertiary endpoints include the quantification of plasma raspberry-derived 81 
(poly)phenols and were subsequently correlated with the primary and secondary end points (pre-82 
specified analysis).  83 
Office blood pressure was measured three times after 10 min of rest using an automated clinical 84 
digital sphygmomanometer (Dynamap, Tampa, FL, USA) with appropriately sized cuff placed 85 
around the upper arm at heart level.  86 
A qualified researcher enrolled participants on the study. Participants and researchers 87 
administering interventions and assessing study outcomes were blinded to the interventions.  An 88 
independent researcher generated the random allocation to treatment sequence (using a Williams 89 
design) and implemented the allocation sequence.  Unblinding was performed after analysis of 90 
primary and secondary outcomes was completed.  An independent researcher in possession of 91 
the blinding codes sent the codes via email to the researchers. Written informed consent was 92 
obtained from all subjects prior to their participation in the study. All studies were conducted 93 
according to the guidelines laid down in the Declaration of Helsinki and all procedures involving 94 
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human subjects were approved by the University of Duesseldorf Research Ethics Committee 95 
(ref: 5327R). The study was also registered with the National Institutes of Health (NIH)-96 
randomized trial records held on the NIH ClinicalTrials.gov website (NCT02734901). This study 97 
was conducted from March 2016 until September 2016. Volunteer recruitment started in March 98 
2016 and was completed within a month. Study visits ran from March 2016 until May 2016 99 
without changes in trial protocol/outcomes. Data collection was performed between April and 100 
September 2016 and statistical analysis were performed in September 2016.  101 
 102 
Raspberry and control test drinks 103 
Drinks were freshly prepared in the mornings of the study visits and were served in opaque 104 
bottles with black straws. Frozen rubus ideaeus (same batch for the whole study) were purchased 105 
at the supermarket (EDEKA, Duesseldorf) and stored at -20 ̊C. The drink containing 400 g of 106 
raspberries was prepared by blending 400 g of frozen raspberries with 100 ml of water. The 107 
drink containing 200 g of raspberries was prepared by blending 200 g of frozen raspberries with 108 
300 ml of water, soluble and insoluble fibers (Pectin, Natura, Brazil; cellulose, Nutricology, 109 
USA, respectively), vitamin C (Clasikool, UK), glucose (Thornton and Ross, UK), fructose 110 
(Special Ingredients, UK), and citric acid (Hexeal chemicals, UK), to match it to the 400 g 111 
raspberry drink (final volume of  both drinks was 592 ml). The placebo drink was micro- and 112 
macronutrient matched to the 400 g raspberry drink, and had the same colour and taste. It was 113 
made by blending soluble and insoluble fibers, sugars, citric acid, red colorant (Red40, 114 
Heitmann, Germany), synthetic raspberry flavor (Lorann Oils, USA) and 550 ml of mineral 115 
water. The intervention drinks were administered on the study days between 7:00 and 11:00 am 116 
in the presence of the researcher to ensure compliance. 117 
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Raspberry (poly)phenol analysis  118 
Freeze-dried raspberry powder was weighted and extracted with 1.5 mL of MeOH:H2O (50:50 119 
v/v). The samples were then sonicated and centrifuged at 15000 g for 15 min at 4 ̊C. A second 120 
extraction was performed on the pellet with 1 ml of the same extraction solvent (total 121 
volume=2.5 ml). After combining supernatants from both extraction steps, samples were filtered 122 
through 0.22 µM PVDF filters and injected directly in the UPLC. 123 
Total ellagitannins were quantified after acid hydrolysis of raspberry samples using a method 124 
previously reported (21, 22). The method was based on the quantification of the acid hydrolysis 125 
products that include ellagic acid and valoneic acid dilactone. The hydrolysis products were 126 
quantified with the calibration curve of ellagic acid at 360 nm. 127 
 128 
Ultrasound measurements of arterial function  and pulse wave analysis 129 
FMD was measured as previously described (23). Briefly, the diameter and flow velocity of the 130 
brachial artery (BA) was measured using a 12 MHz transducer (Vivid I, GE) and automatic 131 
edge-detection software (Brachial Analyzer, Medical Imaging Applications, Iowa City, IA, 132 
USA) yielding standard deviations of mean differences between repeated measurements of less 133 
than 1%. BA diameter was measured 2 cm proximal to the elbow. Reactive hyperemia was 134 
induced by 5 min of distal lower arm occlusion with a sphygmomanometric cuff inflated to 250 135 
mm Hg. After cuff deflation at 0, 20, 40, 60, and 80 sec, the diameter was assessed and FMD 136 
calculated as maximal relative diameter gain relative to baseline. The FMD was expressed as 137 
(diametermax-diameterbaseline)/diameterbaseline x100.  138 
Central blood pressure parameters including augmentation index (AIX) and pulse wave velocity 139 
(PWV) were measured by applanation tonometry using the SphygmoCor® (SMART medical, 140 
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Gloucestershire, UK) system. Via a transfer function, the pressure waveform of the ascending 141 
aorta was synthesized. PWV was determined from measurements taken at the carotid and 142 
femoral artery as previously described (24). 143 
 144 
Biochemical analyses 145 
The blood samples collected in EDTA/heparin tubes were spun (1,700 g; 15 min; 4ºC) 146 
immediately after collection.  Plasma samples for (poly)phenol analysis were spiked with 2% 147 
formic acid and frozen at -80°C until analysis. All clinical chemistry parameters including total, 148 
LDL-, and HDL-cholesterol, triglycerides (enzymatic photometric assay; RocheDiagnostics), 149 
HbA1c, glucose (hexokinase assay) and whole blood count (flow cytometry; Sysmex) were 150 
measured using standard techniques by the Institute for Clinical Chemistry, University Hospital 151 
Duesseldorf, Germany. 152 
 153 
UPLC-Q-TOF MS analysis of plasma and urine (poly)phenols  154 
Plasma and urinary analysis of polyphenol metabolites was performed using microelution solid 155 
phase extraction coupled with UPLC-Q-TOF MS and authentic standards for quantification as 156 
previously described, using a validated method (25). For the identification and quantification of 157 
urolithins, the microbial metabolites of ellagitannins, previously validated methods with UPLC-158 
QTOF MS for plasma samples and HPLC-DAD-Q MS for urine samples were used (26). A 159 
target screening strategy was applied to all the samples for the qualitative screening of possible 160 
ellagic acid derived metabolites. Quantification of urolithins was determined by interpolation in 161 
the calibration curve obtained with their own available standards by peak area integration of its 162 
extracted ion chromatograms. Calibration curves of a mixture of all urolithins (urolithin A 3-163 
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glucuronide, isourolithin A 3-glucuronide, Urolithin A sulfate,  urolithin B glucuronide , 164 
urolithin B sulfate, Urolithin D, urolithin M6, urolithin M7, isourolithin A, urolithin A, and 165 
urolithin B) were prepared in methanol. Total (poly)phenol (TP) concentrations were calculated 166 
based on the sum of all phenolic compounds (59 in plasma and 67 in urine) quantified excl. 167 
urolithins and ellagic acid. 168 
 169 
Power calculation and statistical analysis  170 
Power calculations were performed for the primary endpoint, change in FMD response, using an 171 
online statistical tool (http://hedwig.mgh.harvard.edu/sample_size/size.html). Power was based 172 
on the standard deviation of the difference between two values for the same patient (intra-173 
individual variability) of the operator that performed the FMD analysis (SD=1%). Based on 174 
previous work, we would expect to see a change in FMD of 1-2% (19, 27, 28). At 0.8 power and 175 
at 0.05 significance level, the number of subjects required to detect a difference of 0.720% in the 176 
response of matched pairs in a crossover study is 10. The characteristics of the study population 177 
are expressed as mean values and standard deviations. Changes in FMD values and changes in 178 
plasma and urinary (poly)phenol concentrations were analyzed by one-way ANOVA with 179 
Bonferroni correction. Correlation analysis was performed with Pearson or Spearman tests 180 
depending on normal and non-normal distribution, respectively. Mean values of results are 181 
presented as mean values and their standard error of means, and differences between responses 182 
are presented as mean values and 95% confidence intervals. Analyses were computed with Prism 183 





Baseline characteristics of the study population and tolerance of intervention 187 
The baseline characteristics of the groups of healthy young non-obese males were all within 188 
normal limits (Table 1). All study subjects completed the study, drinks were well tolerated by all 189 
subjects, and no adverse events were reported. 190 
 191 
(Poly)phenol content of the red raspberry drinks 192 
A total of 27 (poly)phenolic compounds were quantified in the raspberry drinks used in the 193 
present study, including 2 ellagitanins, 2 anthocyanins, 5 flavonols, 2 flavan-3-ols, 8 cinnamic 194 
acids, 6 benzoic acids, and 2 benzaldehydes (Table 2). In 200 g and 400 g of raspberries, 201 mg 195 
and 403 mg of (poly)phenolic compounds were quantified, respectively. As expected, 196 
ellagitannins and anthocyanins were the most abundant compounds found in the red raspberries. 197 
 198 
Red raspberry acutely improves endothelial function and this is maintained at 24 h after 199 
consumption 200 
FMD increased significantly by 1.6% (95% CI 1.2%, 1.9%) and 1.2% (95% CI 0.8%, 1.5%) at 2 201 
h post-consumption of the raspberry drink containing 200 g and 400 g of raspberry, respectively, 202 
when compared with the change in FMD due to control drink (Figure 2). When FMD was 203 
measured at 24 h after consumption of 200 g or 400 g raspberries, following a strictly 204 
(poly)phenol-free controlled diet and an overnight fast (12 h), significant increases of 1.0% (95% 205 
CI 0.6%, 1.2%) and 0.7% (95% CI 0.2%, 0.9%) were found as compared to changes due to 206 
control (Figure 2). The FMD changes due to 200 g and 400 g raspberry did not significantly 207 
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differ. No significant changes in peripheral and central blood pressure, PWV, and AIX were 208 
observed between or within treatments at 2 h or 24 h post-consumption (Table 3).  209 
 210 
Identification and quantification of ellagitannin metabolites in plasma and urine  211 
A total of 15 ellagitannin metabolites were identified in plasma and urine, including ellagic acid 212 
and derivatives, urolithins A, B, C and their glucuronide and sulfate conjugates as well as 213 
isourolithin A with corresponding glucuronide and sulfate conjugates. Of these, seven 214 
metabolites were  quantified using authentic standards (Supplementary Table 1). Results from 215 
plasma analysis showed that ellagic acid increased significantly at 2 h post-consumption of the 216 
raspberry drinks, in comparison with control or baseline (Figure 3). At 24 h, urolithin-A-3-217 
glucuronide, urolithin B-glucuronide, urolithin-A-sulfate, urolithin-B-sulfate and total urolithins 218 
significantly increased after consumption of 200 g and 400 g raspberries as compared to baseline 219 
and control drink (Figure 3).  Isourolithin-A-3-glucuronide also increased significantly 220 
(p<0.0001) in plasma at 24 h after consumption of the raspberry drinks but was only found in 2 221 
volunteers (4.2 nM and 15.9 nM after 200 g and 400 g raspberries, respectively). Plasma 222 
urolithin C was only found in one volunteer at 24 h post-consumption of 400 g of raspberries at a 223 
very low concentration (1.0 nM). Other plasma metabolites were identified in some volunteers 224 
but not quantified due to the lack of authentic standards: urolithin-A sulfoglucuronide (n=9, 24 225 
h), urolithin-C sulfate (n=4, 24 h), dimethyl ellagic acid glucuronide (n=9, 2 and 24 h), and 226 
dimethyl ellagic acid (n=1, 2 and 24 h).  227 
Urinary analysis confirmed the presence of urolithin-A, urolithin-A-3-glucuronide, urolithin-A-228 
sulfate, isourolithin-A, isourolithin-A-glucuronide and urolithin-B-glucuronide. Total urolithins 229 
were excreted in significantly higher amounts when comparing 400 g raspberry (5.4 ± 8.4 mg) 230 
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versus control intake (0.1 ± 0.1 mg, p=0.02) over a period of 24 h (Supplementary table 1). Table 231 
5 shows a summary of 24 h urinary excretions of urolithin metabolites. Significant increases in 232 
urolithin-A and urolithin-B-glucuronide were observed after intake of 400 g of raspberries as 233 
compared to control. Iso-urolithin-A-3-glucuronide showed significant increases for both the 200 234 
and 400 g intakes with respect to control. Urolithins had a urinary recovery of 7% and 9% after 235 
intake of 30 mg and 60 mg of ellagitannins respectively (table 5). Out of the ten volunteers, eight 236 
were identified as metabotype A, with urolithin-A-3-glucuronide and urolithin-A sulfate as the 237 
main metabolites and some traces of ellagic acid, whereas two of them were identified as 238 
metabotype B with the presence of isourolithin-A-3-glucuronide, urolithin-B glucuronide and 239 
urolithin-B sulfate in addition to urolithin-A derivatives.  240 
 241 
Identification and quantification of raspberry derived phenolic metabolites in plasma and 242 
urine  243 
Using authentic standards, a total of 59 phenolic metabolites were quantified in plasma 244 
(Supplementary Table 1). Most of the metabolites were conjugated and non-conjugated phenolic 245 
acid derivatives. The total quantified plasma (poly)phenol (TP) concentration was 105±7 μM 246 
(mean±SEM) and 109±10 μM at 2 h and 24 h after consumption of 200 g of raspberries. After 247 
intake of 400 g of raspberries, the TP levels were 112±10 μM at 2h and 120±12 μM at 24 h. TP 248 
were significantly increased (p=0.04) at 24 h after consumption of 400 g of raspberries when 249 
compared to control. Two metabolites (4-methylgallic-3-O-sulfate, and 3,4-250 
dihydroxybenzaldehyde) were significantly increased at 2 h after 400 g of raspberry intake.  251 
Dihydroferulic acid 4-O-β-D-glucuronide, ellagic acid, and pyrogallol-1-O-sulfate were 252 
significantly elevated as compared to control after 2 h of 200 g raspberry intake. Protocatechuic 253 
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acid-4-O-sulfate and ellagic acid showed significant increases 24 h after 400 g of raspberry in 254 
comparison to control. A total of 67 phenolic metabolites were detected in the urine of the 255 
volunteers after intake of raspberries (Supplementary Table 1).  256 
 257 
Ellagitannin-derived phenolic metabolites correlate with the increase in endothelial 258 
function  259 
To link the circulating metabolites with vascular effects, we performed a correlation analysis 260 
between changes in plasma (poly)phenol concentrations and changes in FMD. At 2 h post-261 
consumption of both raspberry drinks,  ellagic acid correlated with FMD. At 24 h post-262 
consumption, urolithin-A-3-glucuronide and urolithin-A-sulfate correlated with FMD, but only 263 




In summary, the current study demonstrate for the first time that the consumption of red 266 
raspberries can increase endothelial function for 24 h and that this effect is associated with 267 
patterns of circulating ellagitanin metabolites in healthy humans.  268 
In the search for the mechanisms of action of dietary (poly)phenols and causality assumptions 269 
related to this, it is essential to consider the pharmacokinetics of these compounds. Most studies 270 
investigating the acute effects of (poly)phenols on endothelial function have reported an early 271 
improvement at 1 to 2 h post-consumption coinciding with peak plasma concentrations of the 272 
phenolic compounds that are, upon ingestion, rapidly absorbed in the small intestine and reach 273 
circulation intact or conjugated by phase II enzymes (24, 29). However, we have recently shown 274 
that (poly)phenol consumption can lead to improvements in FMD for up to 8 hours post-275 
consumption (27, 29). At this time, the majority of the circulating (poly)phenol metabolites are 276 
likely gut microbiome derived phenolic acid metabolites. After blueberry consumption, FMD 277 
increased biphasically with a first peak at 1-2 h that correlated with intestinally absorbed and 278 
metabolized phenolic compounds and a second peak at 6 h that correlated with gut microbial 279 
metabolites (19), and the effects were maintained up to 8 hours post consumption of cranberry 280 
juice (29). It must be noted that no significant differences were found between FMD 281 
improvements after consumption of the 200 and 400 g of raspberries. This agrees with our 282 
previous work, where the effect on FMD plateaued after the consumption of the equivalent to 240 283 
g of blueberries (19). A similar non-linear dose response on FMD was found after consumption 284 
of cranberry juice (29), and in a meta-analysis of randomized controlled trials investigating the 285 
effects of flavonoids on FMD (25).  286 
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The effects that we are reporting here at 2 and 24 hours after consumption coincide with the Cmax 287 
of ellagic acid and urolithins, respectivedly (See Figure 3 and (17)). This indicates that the 288 
vascular effects of raspberries may be driven both by early readily absorbed metabolites and late 289 
gut microbial metabolites of raspberry polyphenols. Ellagic acid was detected in plasma at 2 h 290 
post-consumption, in line with previously reported plasma ellagic acid detection (low nM range) 291 
after 1 h of ellagitannin-rich pomegranate consumption (15). Furthermore, we show that at 24 h 292 
post consumption of red raspberries, urolithin A-sulfate and urolithin A-3-glucuronide reached 293 
higher concentrations in both plasma and urine with respect to baseline and 2h time point (Figure 294 
3). Interestingly, amongst all phenolic compounds quantified upon red raspberry consumption, 295 
only the early and late phase absorbed ellagitannin-derived metabolites correlated with improved 296 
endothelial function in healthy humans, despite many other compounds, in particular the ones 297 
derived from anthocyanins, present in much higher concentration in plasma. To our knowledge, 298 
this is the first time that plasma urolithin A metabolites are linked to improvements in vascular 299 
function as they are present in the blood vessels at the same time as the vascular measurements 300 
and the magnitude of the effects correlates with changes in vascular function. In agreement with 301 
our findings, recently published in vitro work has shown that a mix of urolithin metabolites 302 
significantly increased nitric oxide (NO) bioavailability (30), and urolithin-A and urolithin-A-303 
glucuronide significantly decreased monocyte adhesion and inhibited endothelial cell migration 304 
in vitro (31). This suggests that in particular the late vascular effects of red raspberry may be 305 
caused by gut microbiome derived phenolic metabolites and, therefore, the gut microbiome may 306 
play an important role in mediating beneficial effects of raspberries in healthy humans. It should 307 
be noted that the concentration of urolithin metabolites used in these in vitro studies, although 308 
physiologically relevant, were higher than the ones shown here in the plasma of volunteers. 309 
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Significant increases in urinary excretions of urolithins were observed for both the 200 and 400 g 310 
of raspberry consumption over control (Table 5). Higher concentrations of urolithins were 311 
excreted after consumption of the 400 g raspberries in comparison with the 200 g. This is in 312 
agreement with our previous work showing that circulating levels of (poly)phenol metabolites did 313 
not reach a plateau despite an obvious saturation of vascular effects (19, 29).  314 
 315 
Metabotypes for urolithin production have been recently determined as type A (urolithin A 316 
production), B (isourolithin A and B production) and 0 (non-producers) (32), and differences in 317 
gut dysbiosis and cardiovascular disease risk have been shown among different metabotypes (33). 318 
Obese or overweight subjects, and individuals with metabolic syndrome or colorectal cancer had 319 
a higher percentage of B metabotype than healthy individuals (34). A recent study reported that 320 
only overweight or obese individuals with metabotype B showed improvements in blood lipids 321 
after consumption of ellagitannin-rich pomegranate extract for 3 weeks (33). However, 322 
individuals with metabotype B had higher baseline levels of total and LDL cholesterol than 323 
individuals with metabotype A, which could be the reason why significant changes were 324 
observed only in that group. In our healthy cohort of young normoweight males, we did not see 325 
any differences in baseline characteristics, and although very speculative, we observed a non-326 
significant trend towards increased FMD response in metabotype A (n=8) volunteers as 327 
compared to metabotype B volunteers (n=2). Whether individuals with different metabotypes 328 
may have a different vascular response to ellagitannins deserves further investigation.  329 
Notable limitations of this work are that the study population consisted of a small group of 330 
healthy young men. Therefore, our findings cannot be directly extrapolated to all segments of the 331 
general population. Furthermore, the study was limited in scope and timeframe and, therefore, 332 
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further studies with larger cohorts and over a longer timeframe are needed to investigate whether 333 
the acute effects of raspberry ellagitannins on cardiovascular disease risk biomarkers translate 334 
into health benefits. Administration of purified extracts or purified (poly)phenols underlines the 335 
identification of bioactive metabolites, which is why we remain cautious with the interpretation 336 
that bioactive urolithin metabolites may improve vascular health, as pure ellagitannins were not 337 
included in the study design as a third parallel arm.  338 
 339 
In conclusion, or present data show for the first time that the consumption of dietary achievable 340 
amounts of red raspberries by healthy individuals lead to a clinically relevant improvement in 341 
endothelial function for at least 24 h after consumption, which according to recent meta-analysis 342 
would imply a reduction of 10-15% in CVD risk (35, 36) if sustained over a long enough 343 
timeframe. Furthermore, we linked gut microbial derived plasma urolithin metabolites to vascular 344 
benefits. Further studies will need to show whether our results translate into long-term health 345 
benefits in the general population and whether this is also true for other ellagitannins-rich foods 346 
besides red raspberries - strawberries, pomegranate, or nuts – that may be included as part of a 347 
healthy diet to aid in the prevention of  cardiovascular disease. 348 
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Table 1: Baseline clinical characteristics study population (n=10).   
 Mean ± SD 
Age (years) 27 ± 3 
Weight (kg) 78 ± 8 
BMI (kg/m²) 23 ± 2 
SBP (mmHg) 124 ± 10 
DBP (mmHg) 68 ± 6 
HR (/min) 58 ± 7 
TRIG (mg/dl) 110.3 ± 35.2 
HDL-C (mg/dl) 53 ± 9.3 
LDL-C (mg/dl) 104 ± 19.1 
CRP (mg/dl) 0.2 ± 0.1 























































Raspberry amount (g)  0 (Control) 200  400 
Total (poly)phenols (mg) 0 201 403 
Total ellagitannins (mg) 0 30 60 
Ellagic acid derivatives (mg) 0 23 45 
Valoneic acid dilactone (mg) 0 7.8 15.5 
Total anthocyanins (mg) 0 164 328 
Cyanidin-3-sophoroside (mg) 0 125 251 
Cyanidin-3-glucoside (mg) 0 39 77 
Total flavonols (mg) 0 5.7 11 
Quercetin (mg) 0 0.03 0.05 
Quercetin-sophoroside (mg) 0 2.3 4.6 
Quercetin pentoside (mg) 0 2.2 4.4 
Quercetin-3-glucuronide (mg) 0 1.2 2.4 
Total cinnamic acids (mg) 0 0.7 1.4 
p-Coumaric acid (mg) 0 0.02 0.04 
o-Coumaric acid (mg) 0 0.03 0.06 
Caffeic acid (mg) 0 0.01 0.02 
Ferulic acid (mg) 0 0.02 0.04 
Isoferulic acid (mg) 0 0.58 1.1 
Sinapic acid (mg) 0 0.03 0.06 
Chlorogenic acid (mg) 0 0.00 0.01 
Total flavan-3-ols (mg) 0 0.6 1.2 
Catechin (mg) 0 0.01 0.02 
Epicatechin (mg) 0 0.60 1.2 
Total benzoic acids (mg) 0 0.06 0.11 
2-Hydroxybenzoic acid (mg) 0 0.01 0.02 
3-Hydroxybenzoic acid (mg) 0 0.01 0.01 
2,5-Dihydroxybenzoic acid (mg) 0 0.00 0.01 
Protocatechuic acid (mg) 0 0.01 0.02 
Gallic acid (mg) 0 0.02 0.04 
Total benzaldehydes (mg) 0 0.02 0.03 
3,4-Dihydroxybenzaldehyde (mg) 0 0.01 0.03 
Mineral water (ml) 550 350 150 
Glucose (g) 7.4 7.4 7.4 
Fructose (g) 9.4 9.4 9.4 
Fiber (g) 17.4 17.4 17.4 
Citrate (g) 8 8 8 
Vitamin C (g) 0.105 0.105 0.105 
Total volume (ml) 592 592 592 
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Table 3: Effects of intervention raspberry drinks on vascular function.  
 
 
Outcomes are expressed as absolute values with SD and as difference of the changes with respect to baseline with 95% CI. Testing was 
done with one-way ANOVA calculations (Bonferroni correction) comparing changes with respect to baseline between treatments for 
each time point. * represent values that do not span zero and are thus significant. A significant difference in FMD was observed for the 
200 g and 400 g raspberry intake as compared to control. No significant differences in FMD were observed between the 200 and 400 g 
raspberry intakes. FMD, flow-mediated dilation; PSBP, peripheral diastolic blood pressure; PDBP, peripheral systolic blood pressure; 
CSBP, central systolic blood pressure; CDBP, central diastolic blood pressure; HR, heart rate; PWV, pulse-wave velocity; AIx, 
augmentation index. 
 Control 200 g raspberries 400 g raspberries Difference (Δ200 g - 
Δcontrol) 
Difference (Δ400 g - 
Δcontrol) 
 Baseline 2h 24h Baseline 2h 24h Baseline 2h 24h 2h 24h 2h 24h 








 (0.2, 0.9)* 
PSBP 
(mmHg) 
127.2±9.9 126.1±11.4 122.4±9.9 124.6±9.8 121.2±10.0 123.0±9.4 120.7±12.8 121.4±9.1 118.5±13.7 
2.3  
( -4.1, 8.7) 
-3.1  
( -9.5, 3.2) 
4.0  
( -2.4, 10.4) 
-0.6 
 ( -7.0, 5.8) 
PDBP 
(mmHg) 
70.8±7.8 68.8±8.3 64.7±8.0 69.6±7.6 68.9±6 68.3±9.5 68.7±6.5 69.7±8.2 66.8±9.0 
-1.3  
( -6.7, 4.1) 
-4.9  
( -10.3, 0.5) 
1.7  
( -3.7, 7.1) 
-0.7 
 ( -6.1, 4.7) 
CSBP 
(mmHg) 
105.5±8.3 102.7±9.1 102.2±9.6 105.1±8.4 101.2±7.4 101.9±5.7 102.7±10.0 102.5±7.6 99.3±9.6 
0.2  
( -4.7, 5.1) 
-1.0  
( -5.9, 3.9) 
2.8  
( -2.1, 7.7) 
-1.1 
 ( -6.0, 3.8) 
CDBP 
(mmHg) 
71.4±8.0 69±8.2 66.9±10.2 70.9±7.1 70.2±6.3 69.8±7.4 69.4±7.1 73.5±10.7 68.7±9.0 
-2.4  
( -7.8, 3.0) 
-4.1  
( -9.5, 1.3) 
4.1  
( -1.3, 9.5) 
-0.3 
 ( -5.7, 5.1) 
HR (bpm) 60.9±8.2 56.8±6.1 60±7.6 58.5±10.0 55.4±7.2 61.7±11.1 56.9±7.9 56.8±7.4 60.3±8.4 
-1.1  
( -8.1, 5.9) 
-4.2  
( -11.2, 2.8) 
3.0  
( -4.0, 10.0) 
0.2 
 ( -6.8, 7.2) 








 (-2.3, 1.1) 





( -17.5, 4.9) 
-6.5  
( -17.7, 4.7) 
-5.2  
( -16.4, 6.0) 
-7.5 




Table 4: Plasma (poly)phenols and vascular function correlation analysis.  
 (Poly)phenols 
  Δ FMD 2 h  Δ FMD 24 h 
 ρ p  ρ p 
200 g raspberry (n = 10) 
Ellagic acid 0.78 0.01 - - 
Urolithin-A-3-glucuronide - - 0.64 0.05 
Urolithin-A-sulfate - - 0.80 0.01 
400 g raspberry (n = 10) Ellagic acid 0.51 0.02 - - 
Significant correlations (p<0.05) between plasma raspberry derived (poly)phenol metabolites and 
changes in FMD with respect to baseline at 2 h or 24 h after consumption of 200 and 400 g 





Table 5: Urinary excretion of urolithin metabolites.  
 
Excretions were calculated based on the amount of total ellagitannins taken by the volunteers (30 
and 60 mg). Urolithin-A and Urolithin-B-glucuronide showed significant increases after 400 g of 
raspberries with respect to control. Iso-urolithin-A-3-glucuronide showed significant increases in 
both doses with respect to control. One-way ANOVA with Bonferroni correction was used to 
determine significance. Marked results with asterixes indicate significant differences in excreted 
amounts over control. No significant differences in excretion were observed between the two doses 





200  g raspberries 
(30 mg 
ellagitannins) 
400 g raspberries 
(60 mg ellagitannins) 
 µg  µg  µg  
Urolithin-A (n = 10) 0 ± 0 14 ± 0 172 ± 88** 
Urolithin-A sulfate (n = 10) 0 ± 0 50 ± 0 295 ± 0 
Urolithin-A-3-glucuronide (n = 10) 525 ± 232 1,488 ± 223 4,282 ± 2,757 
Urolithin-B-glucuronide (n = 2) 0 ± 0 1,894 ± 57 2,985 ± 2,145** 
Iso-urolithin-A (n = 2) 0 ± 0 6 ± 0 27 ± 0 
Iso-urolithin-A-3-glucuronide (n = 2) 0 ± 0 965 ± 614* 1,716 ± 567*** 
Total urolithins (n = 10) 525 ± 232 2,131 ± 465 5,420 ± 2,812 





Figure 1: Consort study flow (A) and study design (B) schemes 
Figure 2: Changes in flow-mediated dilation (FMD) respect to baseline after consumption of the 
raspberry drinks containing 0, 201, and 403 mg of (poly)phenols. Significance was tested using 
repeated measurements two-way ANOVA with Bonferroni corrections where **p<0.01 and 
****p<0.0001 significantly different from control. Values are represented as Mean ± SEM (n = 
10). 
Figure 3: Timecourse of the main ellagitannin metabolites quantified in plasma after intake of 
control, 201 mg and 403 mg total (poly)phenols(TP): A) total urolithins, B) ellagic acid, C) 
urolithin A sulfate, D) urolithin A-3-O-glucuronide, E) urolithin B glucuronide, F) urolithin B 
sulfate. Significance was tested using a repeated measures two-way ANOVA with Bonferroni 
corrections where *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001  as significantly different 
from control. Values are represented as Mean ± SEM (n = 10). 
 
Supplementary Material captions: 
Supplementary Table 1: (Poly)phenol plasma concentrations (nM) and urinary excretions after 
intake of 400 g of raspberries. Values are represented as Mean ± SEM (n = 10) 
Supplementary Figure 1: Individual correlation plots of ellagitannin metabolites with changes in 
FMD (Table 4): A) Ellagic acid (2 h after intake of 200 g raspberries), B) Ellagic acid (2 h after 
intake of 400 g raspberries), C) Urolithin A-sulfate (24 h after intake of 200 g raspberries and D) 
Urolithin A-glucuronide (24 h after intake of 200 g raspberries. Values are represented in nM 
concentrations (n = 10). Correlation analysis of the non-parametric data was assessed using a 
Spearman’s test. 
